Participating Companies

Ad­di­tio­n­al prod­ucts are 4SC-202, an epi­ge­net­ic an­ti-can­cer com­pound that has com­plet­ed Phase I clin­i­cal trial for the treat­ment of he­ma­to­log­i­cal tu­mors; and 4SC-205, an an­ti-can­cer com­pound, which has com­plet­ed Phase I clin­i­cal trial for the treat­ment of solid tu­mors. [more in­for­ma­tion]
Affimed N.V. [AFMD] US$289 MM MCap
NK cell en­gager AFM13 (CD30/CD16A) to en­ter a Phase 2 reg­is­tra­tion study in CD30-pos­i­tive pe­ripher­al T cell lym­pho­ma and an in­vesti­ga­tor-spon­sored study by MDACC of AFM13 com­bined with al­lo­gene­ic NK cells in re­lapsed/re­frac­to­ry CD30-pos­i­tive lym­pho­ma. [more in­for­ma­tion]
Allecra Therapeutics
En­me­ta­zobac­tam is an ex­tend­ed-spec­trum ß-lac­ta­mase in­hibi­tor be­long­ing to the peni­cil­lan­ic acid sul­fone class that ex­hibits po­tent in vit­ro and in vi­vo ac­tiv­i­ty against many re­sis­tant Gram-neg­a­tive patho­gens. [more in­for­ma­tion]
AM-Pharma B.V.
Treat­ing sep­sis as­so­ci­at­ed acute kid­ney in­jury (AKI) with pro­pri­e­tary re­com­bi­nant al­ka­line phos­pha­tase (re­cAP). Re­sults from Ph 2 trial in 300+ pts, de­mon­s­trat­ed rel­a­tive im­prove­ment of 40%+ OS in re­cAP group. Ini­ti­at­ing Ph 3 in Q3 2020 – in­ter­im look (n=400) exp Q3 2021 (P end­point: Day 28 all-cause mor­tal­i­ty). [more in­for­ma­tion]
Phase 3 ready, Tevere­lix, a long act­ing in­jectable pep­tide GnRH an­ta­g­on­ist. Lead in­di­ca­tion for pros­tate can­cer, fol­lowed by be­nign pro­stat­ic hy­per­pla­sia (BPH), acute uri­nary re­ten­tion (AUR), uterine fi­broids and en­dometrio­sis. Over 450 sub­jects have been dosed over 850 times to date with no se­ri­ous ad­verse re­ac­tions and good lo­cal tol­er­ance. [more in­for­ma­tion]
Arvelle Therapeutics
Arvelle is head­quar­tered in Switz­er­land and re­ceived start-up fi­nanc­ing of $207.8 mil­lion, one of the largest ini­tial fi­nanc­ing com­mit­ments for a Eu­ro­pean-fo­cused bio­phar­ma­ceu­ti­cal com­pany, with in­vest­ments from a glob­al syn­di­cate in­clud­ing No­vaQuest Cap­i­tal Ma­n­age­ment, BRV Cap­i­tal Ma­n­age­ment, LSP, H.I.G. [more in­for­ma­tion]
ATAI Life Sciences AG
ATAI is a glob­al biotech com­pany builder that lev­er­ages a de­cen­tral­ized, tech­nol­o­gy- and da­ta-driv­en plat­form mod­el to serve mil­lions of peo­ple suf­fer­ing from men­tal health di­s­or­ders. ATAI is com­mitt­ed to ac­quir­ing and ef­fi­cient­ly de­vel­op­ing in­no­va­tive treat­ments that ad­dress sig­ni­f­i­cant un­met med­i­cal needs and lead to paradigm shifts in the men­tal health space. [more in­for­ma­tion]
Avacta [AVCT:LN] £380 MM MCap
UK-based com­pany de­vel­op­ing pro­pri­e­tary next-gen anti­bodies called Af­fimers. Avac­ta is a new Trout client that is a bit un­der the ra­dar with limit­ed US-ex­po­sure to date. They are a bit small/ear­ly but we have been gett­ing in­ter­est so far on their ap­proach – sim­i­lar con­cept to Ab­l­ynx, part­n­er­ship with Mod­er­na, etc. Af­fimers are 10X small­er than tra­di­tio­n­al anti­bodies that are easy to for­mat, high­ly spe­cif­ic, easy to man­u­fac­ture, mul­ti­ple routes of ad­min­is­tra­tion, etc. – com­para­ble to Ab­l­ynx’s nan [more in­for­ma­tion]
BioNTech AG [BNTX] US$15,924 MM MCap
Through its di­ver­si­fied tech­nol­o­gy plat­forms and in-house di­ag­nos­tics and man­u­fac­tur­ing units, BioN­Tech is strate­g­i­cal­ly po­si­tioned to im­ple­ment its lab-bench-to-mar­ket strat­e­gy. [more in­for­ma­tion]
Calliditas Therapeutics [CALT] US$584 MM MCap
Cal­lid­i­tas is fo­cused on the de­vel­op­ment and com­mer­cial­iza­tion of its lead prod­uct can­di­date Ne­fe­con, which has suc­cess­ful­ly com­plet­ed a Phase 2b clin­i­cal trial, as a po­ten­tial new treat­ment for pa­tients with in­flam­ma­to­ry kid­ney dis­ease (IgA nephro­pa­thy) who are at risk of pro­gress­ing to re­nal fail­ure. [more in­for­ma­tion]
Cellestia Biotech AG
The com­pany's drugs of­fer a mode of ac­tion for the treat­ment of NOTCH de­pen­dent leukemias, lym­pho­mas and solid tu­mors through oral med­i­ca­tion, en­abling pa­tients to get ef­fi­cient treat­ment and en­sure a fast re­cov­ery. Celles­tia is com­plet­ing a Phase l first-in-man clin­i­cal trial with CB-103 treat­ing can­cer pa­tients in the EU. [more in­for­ma­tion]
Curetis AG [CURE:AS] €8 MM MCap
Curetis’ Un­yvero Sys­tem is a ver­satile, fast and high­ly au­to­mat­ed molec­u­lar di­ag­nos­tic plat­form for easy-to-use, car­tridge-based so­lu­tions for the com­pre­hen­sive and rapid de­tec­tion of patho­gens and an­timi­cro­bial re­sis­tance mark­ers in a range of se­vere in­fec­tious dis­ease in­di­ca­tions. [more in­for­ma­tion]
CureVac AG [CVAC] US$8,130 MM MCap
Cure­vac is a pri­vate Ger­man com­pany with mR­NA plat­form, di­ver­si­fied pipe­line, and three lead pro­grams in ph1: CV8102 (vari­ous can­cer in­di­ca­tions), CV9202 (NS­CLC) and CV7202 (Ra­bies). Last fi­nanc­ing round done at over $1bn. Other com­pa­nies in the space: MR­NA, TBIO, BN­TX. [more in­for­ma­tion]
Deutsche Bank AG [DB] US$17,011 MM MCap
Deutsche Bank’s ADR team is part of the Trust & Agen­cy Ser­vices busi­ness within the new­ly cre­at­ed Cor­po­rate Bank Di­vi­sion. Deutsche Bank was ap­point­ed as DR Bank for the largest Life Sci­ences sec­tor ADR IPO of 2019 with the $582m Nas­daq list­ing of Genmab A/S, con­firm­ing our po­si­tion as the lead­ing is­suer of cap­i­tal in the US ADR mar­kets. [more in­for­ma­tion]
Donnelley Financial Solutions [DFIN] US$453 MM MCap
Don­nel­ley Fi­nan­cial (DFIN) works with Biotech and Phar­ma com­pa­nies glob­al­ly pro­vid­ing pre­pa­ra­tion plat­forms used for tran­s­ac­tio­n­al pro­cess­es in­clud­ing; Don­nel­ley Fi­nan­cial is the mar­ket lead­er in vir­tu­al da­ta rooms, SEC fil­ings and IPO reg­is­tra­tions. [more in­for­ma­tion]
Ernst & Young
[more in­for­ma­tion]
As a re­sult, Ethris is fo­cused in­ter­nal­ly on a strate­g­ic set of metabolic and re­s­pi­ra­to­ry di­s­or­ders, and works with part­n­ers to re­al­ize the po­ten­tial for its pa­tent­ed SN­IM®RNA Tran­script Ther­a­pies in other ar­eas of hu­man dis­ease. [more in­for­ma­tion]
Ethris GmbH
Ethris is pav­ing a new path from genes to ther­a­peu­tic pro­teins us­ing its pro­pri­e­tary mes­sen­ger RNA tech­nol­o­gy plat­form, which en­ables the dis­cov­ery, de­sign and de­vel­op­ment of tran­script ther­a­pies that re­s­tore miss­ing func­tions in pa­tients’ cells and tis­sues. Ethris is ad­vanc­ing tran­script ther­a­pies to trans­form the treat­ment of dis­ease. [more in­for­ma­tion]
Euronext [EUXTF] US$8,253 MM MCap
A strong pan-Eu­ro­pean pres­ence gives ac­cess to our reg­u­lat­ed mar­kets in Am­s­ter­dam, Brus­sels, Dublin, Lis­bon and Paris. Of­fices span­n­ing three conti­nents serve clients of our glob­al prod­ucts and ser­vices. We draw on each lo­cal mar­ket's strengths while pro­vid­ing scale and reach. [more in­for­ma­tion]
Formycon AG [FYB:FF] €303 MM MCap
Formy­con AG is a Ger­man-based (Mu­nich/Martin­s­ried) in­de­pen­dent de­vel­op­er of Biosim­i­lars for the reg­u­lat­ed mar­kets. Our lead prod­uct is a biosim­i­lar can­di­date for Lu­cen­tis which is in clin­i­cal phase III and there­fore is (to our knowl­edge) the most ad­vanced biosim­i­lar can­di­date for Lu­cen­tis glob­al­ly. [more in­for­ma­tion]
GE Healthcare
[more in­for­ma­tion]
Genkyotex SA
Genky­o­tex is de­vel­op­ing a pipe­line of first-in-class prod­uct can­di­dates tar­get­ing one or mul­ti­ple NOX en­zymes. Its se­cond prod­uct can­di­date, GK­T771, is a NOX1 in­hibi­tor tar­get­ing mul­ti­ple path­ways in an­gio­ge­n­e­sis, pain pro­cess­ing, and in­flam­ma­tion, cur­rent­ly un­der­go­ing pre­clin­i­cal test­ing. [more in­for­ma­tion]
Glycostem Therapeutics
Gly­costem Ther­a­peu­tics is a Dutch biotech com­pany. Gly­costem Ther­a­peu­tics is the trade name of the le­gal en­ti­ty IPD Ther­a­peu­tics BV, which has been estab­lished in De­cem­ber 2007. Gly­costem Ther­a­peu­tics has de­vel­oped the world's first GMP com­pliant NK-cell plat­form that is ready for in­dus­trial scale-up. [more in­for­ma­tion]
Goldman Sachs & Co.
Gold­man Sachs & Co. (U.S.) is a full-ser­vice glob­al in­vest­ment bank that of­fers equi­ty and fixed in­come re­search ser­vices to in­sti­tu­tio­n­al in­ves­tors. The firm is head­quar­tered in New York and main­tains of­fices in 23 coun­tries world­wide and was found­ed in 1829. [more in­for­ma­tion]
Goodwin Procter LLP
More than 1,000 cor­po­rate and liti­ga­tion at­tor­neys lev­er­age their spe­cif­ic ex­pe­ri­ence and as­sem­ble full-ser­vice teams to ad­vise clients in th­ese and ad­ja­cent in­dus­tries. [more in­for­ma­tion]
Immatics NV [IMTX] US$664 MM MCap
Im­mat­ics com­bines the dis­cov­ery of true tar­gets for can­cer im­munother­a­pies with the de­vel­op­ment of the right T cell re­cep­tors with the goal of en­abling a ro­bust and spe­cif­ic T cell re­sponse against th­ese tar­gets. We are com­mitt­ed to de­liv­er­ing the pow­er of T cells and to un­lock­ing new av­enues for pa­tients in their fight against can­cer. [more in­for­ma­tion]
Immutep (formerly Prima BioMed) [IMMP] US$82 MM MCap
Cur­rent trials: IM­P321 Ph2b (AI­PAC), po­ten­tial­ly EU-reg­is­tra­tio­n­al, for me­tastat­ic breast can­cer, top line da­ta 1H 2019; and IM­P321 Ph1 (TAC­TI-mel) for me­tastat­ic me­lano­ma, safe­ty and dose es­ca­la­tion da­ta due 1H 2018. CMO/CSO Fr&ea­cute;d&ea­cute;ric Trie­bel dis­cov­ered the LAG-3 gene in 1990 and iden­ti­fied the func­tions and med­i­cal ap­pli­ca­tions of the tar­get. [more in­for­ma­tion]
InflaRx N.V. [IFRX] US$120 MM MCap
Com­ple­ment sys­tem fo­cused com­pany, de­vel­op­ing an­ti C5a mAbs with ap­pli­ca­tions in com­plex car­di­ac surgery, hi­dra­denits, AN­CA as­soc. Re­port­ed pos­i­tive Ph2a re­sults with IFX-1 in Jan­uary 2015. Fol­low-on molecule, IFX-2, in pre-clin­i­cal de­vel­op­ment for ad­di­tio­n­al sub-acute, chron­ic in­flam­ma­to­ry in­di­ca­tions. [more in­for­ma­tion]
Jefferies LLC [JEF] US$4,681 MM MCap
In late 2002, Jef­feries & Com­pany (U.S. The firm was found­ed in 1962 by Boyd Jef­feries and is head­quar­tered in New York and has of­fices world­wide. Leu­ca­dia Na­tio­n­al Cor­po­ra­tion ac­quired Jef­feries Group, LLC on March 1, 2013, on­the same day Jef­feries & Com­pany (U.S. [more in­for­ma­tion]
Kaminari Medical
In 2015, Coro­nary Artery Dis­ease (CAD) af­fect­ed 110 mil­lion peo­ple and re­sult­ed in 8.9 mil­lion deaths world­wide. CAD oc­curs when the ar­teries that sup­p­ly the heart mus­cle with blood be­come har­d­ened and nar­rowed, due to the buildup of choles­terol and plaque on their in­n­er walls. [more in­for­ma­tion]
Leukocare AG
A pri­vate­ly owned, prod­uct-fo­cused, clin­i­cal-stage biotech­nol­o­gy com­pany found­ed in 2003 and head­quar­tered in Martin­s­ried/Mu­nich, Ger­many. [more in­for­ma­tion]
MagForce AG [MF6.DE]
The tech­nol­o­gy and its re­lat­ed equip­ment are cur­rent­ly in the fi­nal phas­es of clin­i­cal trials. Un­til th­ese have been suc­cess­ful­ly con­clud­ed, the prod­ucts can on­ly be used in con­junc­tion with clin­i­cal trials. The prod­ucts can on­ly be sold and used in nor­mal clin­i­cal prac­tice once they have re­ceived reg­u­la­to­ry ap­pro­val from the re­spon­si­ble au­thor­i­ties. [more in­for­ma­tion]
MC Services AG
MC Ser­vices is an in­ter­na­tio­n­al Cor­po­rate Com­mu­ni­ca­tions and In­ves­tor Re­la­tions firm pro­vid­ing Life Sci­ences com­pa­nies high-lev­el con­sul­tan­cy, tar­get­ed ser­vices and sup­port through­out Eu­rope and be­yond [more in­for­ma­tion]
Medigene AG [MDG1:DB] €99 MM MCap
blue­bird bio col­lab; BLUE ini­ti­at­ing trial w/MDG MAGEA-4 can­di­date in 2020. TCRs tar­get­ing HA-1 & MAGE-A1 in de­vt. . DC vax in on­go­ing Ph 1/2; fi­nal read­out in 2019. [more in­for­ma­tion]
Merck Serono
At EMD Serono, the bio­phar­ma­ceu­ti­cal busi­ness of Mer­ck KGaA, Darm­s­tadt, Ger­many in the U.S., we work to trans­form lives by de­vel­op­ing and de­liv­er­ing mean­ing­ful ther­a­pies, and work­ing to tru­ly un­der­s­tand and re­spond to the ther­a­peu­tic and sup­port needs of in­di­vi­d­u­al pa­tients. [more in­for­ma­tion]
[more in­for­ma­tion]
[more in­for­ma­tion]
Our main agen­cies stand in all over France and Ger­many, but al­so in New York, Ma­drid, Mi­lan, Zurich, Gene­va, Tu­nis, Sin­ga­pore, Hong-Kong, Cairo, Abu Dhabi and Ho Chi Minh Ci­ty. To of­fer our clients - pri­vate clients, com­pa­nies, in­sti­tu­tio­n­al in­ves­tors, IFAs - our in-depth ex­per­tise in fi­nan­cial mar­kets. [more in­for­ma­tion]
Oxurion [TG4:FF] €93 MM MCap
Ox­u­ri­on is a bio­phar­ma­ceu­ti­cal com­pany de­vel­op­ing treat­ments to pre­serve vi­sion for pa­tients with dis­eas­es af­fect­ing the back of the eye. Ox­u­ri­on owns the glob­al rights to Je­trea (ocri­plas­min), the on­ly phar­ma­co­log­i­cal vit­re­ol­y­sis drug ap­proved for the treat­ment of symp­to­mat­ic vit­re­o­mac­u­lar ad­h­e­sion (in the U.S. [more in­for­ma­tion]
Remi­ma­zo­lam: short-act­ing anes­thet­ic. Ph 3 study in pro­ce­du­ral se­da­tion in US. Safe­ty da­ta in ASA III/IV pa­tients in Ph 3 colonos­copy study and Ph 3 bron­chos­copy study. US ap­pro­val filed by part­n­er Cos­mo Phar­ma­ceu­ti­cals in June 2019. Ini­ti­at­ed Ph 3 in gen­er­al anes­th­e­sia in EU in Ju­ly 2018, exp com­ple­tion 2020. [more in­for­ma­tion]
Pharming Group NV [PHARM:AS] €599 MM MCap
RU­CON­EST (rhC1INH), the on­ly re­com­bi­nant en­zyme re­place­ment ther­a­py mar­ket­ed for acute Hered­i­tary An­gioede­ma (HAE) at­tacks and be­ing de­vel­oped for large un­met in­di­ca­tions. [more in­for­ma­tion]
Phar­varis is fo­cused on bring­ing an oral bradykinin B2 re­cep­tor an­ta­g­on­ist to pa­tients for use as an al­ter­na­tive to in­ject­ed ther­a­pies for hered­i­tary an­gioede­ma (HAE) and other B2 re­cep­tor-me­di­at­ed in­di­ca­tions. Phar­varis us­es small molecules to ad­vance po­tent, oral­ly avai­l­able com­pounds tar­get­ing HAE. [more in­for­ma­tion]
PROMETHERA Biosciences S.A.
Promethera Bio­s­ciences is a glob­al in­no­va­tor in liv­er ther­a­peu­tics whose mis­sion is to bring life-sav­ing treat­ments to re­duce the need for liv­er tran­s­plan­ta­tion. In ad­di­tion to our cell-based pipe­line, we de­vel­op anti­body tech­nolo­gies such as the an­tiT­NF-R1 anti­body Atrosimab, to com­ple­ment and di­ver­si­fy our ther­a­peu­tic op­tions. [more in­for­ma­tion]
Ryvu Therapeutics [RVU:WAR]
Po­ten­tial first in class CD­K8 in­hibi­tor for leukemias, lym­pho­mas, and solid tu­mors in Ph1b in AML and high-risk MDS, PIM/FLT3 ki­nase in­hibi­tor in Ph 1/2 in AML (part­nered w Me­nari­ni). Da­ta in 2020. Ear­ly stage pipe­line ad­dress­ing emerg­ing solid tu­mor tar­gets. [more in­for­ma­tion]
Silicon Valley Bank
For more than 30 years, Sil­i­con Val­ley Bank (SVB) has helped in­no­va­tive com­pa­nies and their in­ves­tors move bold ideas for­ward, fast. With com­mer­cial, in­ter­na­tio­n­al and pri­vate bank­ing ser­vices, SVB helps ad­dress the unique needs of in­no­va­tors. Forbes named SVB one of Amer­i­ca’s best banks (2015) and one of Amer­i­ca’s best-ma­n­aged com­pa­nies (2014). [more in­for­ma­tion]
Solebury Capital
Sole­bury Cap­i­tal LLC is a glob­al ad­vi­so­ry firm and reg­is­tered bro­k­er deal­er ex­clu­sive­ly fo­cused on the equi­ty cap­i­tal mar­kets. We pro­vide our cor­po­rate and fi­nan­cial spon­sor clients with in­de­pen­dent ad­vice, ex­pe­ri­enced judg­ment and tran­s­ac­tion ma­n­age­ment ser­vices – em­pow­er­ing them to make more ful­ly in­formed de­ci­sions at all points in the un­der­writ­ing pro­cess. [more in­for­ma­tion]
Solebury Trout
With al­most two de­cades of ex­pe­ri­ence in the biotech­nol­o­gy, phar­ma­ceu­ti­cal, med­i­cal tech­nol­o­gy and life sci­ence tech­nol­o­gy sec­tors, the Trout Group of­fers its clients the knowl­edge base need­ed to clar­i­fy in­vest­ment themes and lev­er­age key re­la­tion­ships for in­creased ex­po­sure to the prop­er au­di­ence. [more in­for­ma­tion]
SOTIO a.s.
SO­TIO pur­sues this goal through its the SO­TIO® in-house re­search and clin­i­cal de­vel­op­ment and re­lat­ed ser­vices, col­lab­o­ra­tions with ex­ter­nal part­n­ers, in-li­cens­ing deals, in­vest­ments and ac­qui­si­tions. [more in­for­ma­tion]
State Street Global Advisors
For near­ly four de­cades, State Street Glob­al Ad­vi­sors has helped our clients and those who re­ly on them to in­vest re­spon­si­b­ly, en­abling eco­nom­ic pros­per­i­ty and so­cial progress. [more in­for­ma­tion]
sterna biologicals
By tar­get­ing tran­scrip­tion fac­tors that play a cen­tral role in reg­u­lat­ing Th1- and Th2-driv­en in­flam­ma­to­ry mech­anisms, the Com­pany’s pro­pri­e­tary DNAzyme-based drug can­di­dates can in­ter­vene with up­stream in­flam­ma­to­ry pro­cess­es to ad­dress re­lat­ed dis­eas­es more ef­fec­tive­ly. Ster­na cur­rent­ly has four pro­grams in phase 2 de­vel­op­ment. [more in­for­ma­tion]
Susquehanna Financial Group LLP
Susque­han­na Fi­nan­cial Group, LLP pro­vides equi­ty re­search and bro­k­er­age ser­vices. The com­pany of­fers re­search re­ports, alerts, and in­sights. Susque­han­na Fi­nan­cial Group, LLP op­er­ates as a sub­si­diary of Susque­han­na In­ter­na­tio­n­al Group, LLP. [more in­for­ma­tion]
SVB Leerink
SVP Leerink is a full-ser­vice in­vest­ment bank that of­fers equi­ty re­search ser­vices to in­sti­tu­tio­n­al and re­tail in­ves­tors. The firm al­so of­fers in­sti­tu­tio­n­al sales/trad­ing, cor­po­rate fi­nance, and as­set ma­n­age­ment ser­vices. Leerink Part­n­ers, LLC al­so us­es anal­y­sis from ME­DA­Corp, a pri­vate­ly held com­pany that pro­vides biomed­i­cal con­sult­ing ser­vices. [more in­for­ma­tion]
Synaffix BV
[more in­for­ma­tion]
Targovax [TRVX:OS] NKr624 MM MCap
Pre­lim­i­nary Ph1b da­ta of OV ON­COS-102+che­mo in me­sothe­lio­ma re­sults: com­bo mPFS=8.4 mos. vs. con­trol mPFS=6.8 mos.; 1L pts mPFS-8.9 mos. Up­com­ing mile­s­tones: up­dat­ed clin­i­cal & im­mune da­ta in Ph2 me­sothe­lio­ma (1H20); pre­clin­i­cal da­ta on next-gen OV w/ dou­ble trans­genes (1H20); and clin­i­cal da­ta from Ph1 me­lano­ma study, part 2 with ex­tend­ed dos­ing (2H20). [more in­for­ma­tion]
Vaccitech Limited
Pro­pri­e­tary ChA­dOx (prime) and MVA (boost) tech­nol­o­gy plat­form in­duces and main­tains CD8+ T-cells at the max­i­mum lev­els pub­lished to date. Ph1/2 da­ta for HPV and HBV im­munother­a­pies ex­pect­ed 2H20. En­cour­ag­ing pros­tate can­cer, 5T4 im­munother­a­peu­tic da­ta re­cent­ly re­leased. Ph1/2 NS­CLC MAGE-NYE­SO im­munother­a­peu­tic en­ters clin­ic in Q1 2021. ChA­dOx COVID-19 vaccine out-li­censed to Ox­ford Uni/As­traZene­ca with post-pan­dem­ic rev­enue stream. $150M fund­ing at Jen­n­er In­sti­tute and com­pany raised $48M since for­ma­tion [more in­for­ma­tion]